Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide

Nat Rev Urol. 2016 Dec;13(12):697-698. doi: 10.1038/nrurol.2016.212. Epub 2016 Nov 2.

Authors

Gerhardt Attard¹, Emmanuel S Antonarakis²

Affiliations

¹ Centre of Evolution and Cancer, The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK; and at The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.
² Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, Maryland 21231, USA.

PMID: 27804988
DOI: 10.1038/nrurol.2016.212

No abstract available

Publication types

Review

MeSH terms

Androstenes / pharmacology
Androstenes / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Benzamides
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics*
Humans
Male
Nitriles
Phenylthiohydantoin / analogs & derivatives*
Phenylthiohydantoin / pharmacology
Phenylthiohydantoin / therapeutic use
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / genetics
Prostatic Neoplasms / metabolism
Prostatic Neoplasms, Castration-Resistant / drug therapy
Prostatic Neoplasms, Castration-Resistant / genetics*
Prostatic Neoplasms, Castration-Resistant / metabolism
Receptors, Androgen / genetics*
Receptors, Androgen / metabolism

Substances

Androstenes
Antineoplastic Agents
Benzamides
Nitriles
Receptors, Androgen
Phenylthiohydantoin
enzalutamide
abiraterone